Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Brain Hyperconnectivity >10 Years After Cisplatin-Based Chemotherapy for Testicular Cancer.

Stouten-Kemperman MM, de Ruiter MB, Boogerd W, Kerst JM, Kirschbaum C, Reneman L, Schagen SB.

Brain Connect. 2018 Sep;8(7):398-406. doi: 10.1089/brain.2017.0569. Epub 2018 Sep 6.

PMID:
29999422
2.

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.

de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O.

Neoplasia. 2018 Jul;20(7):710-720. doi: 10.1016/j.neo.2018.05.001. Epub 2018 May 28.

3.

Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib.

Compter A, Boogerd W, van Thienen JV, Brandsma D.

Neurol Clin Pract. 2017 Oct;7(5):418-420. doi: 10.1212/CPJ.0000000000000331. No abstract available.

4.

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

Geukes Foppen MH, Boogerd W, Blank CU, van Thienen JV, Haanen JB, Brandsma D.

Melanoma Res. 2018 Apr;28(2):126-133. doi: 10.1097/CMR.0000000000000429.

PMID:
29356790
5.

Changes in brain white matter integrity after systemic treatment for breast cancer: a prospective longitudinal study.

Menning S, de Ruiter MB, Veltman DJ, Boogerd W, Oldenburg HSA, Reneman L, Schagen SB.

Brain Imaging Behav. 2018 Apr;12(2):324-334. doi: 10.1007/s11682-017-9695-x.

PMID:
28290072
6.

Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type.

Menning S, de Ruiter MB, Veltman DJ, Boogerd W, Oldenburg HS, Reneman L, Schagen SB.

PLoS One. 2017 Mar 7;12(3):e0171724. doi: 10.1371/journal.pone.0171724. eCollection 2017.

7.

Leptomeningeal metastases: a RANO proposal for response criteria.

Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA.

Neuro Oncol. 2017 Apr 1;19(4):484-492. doi: 10.1093/neuonc/now183. Review.

8.

Cognitive Impairment in a Subset of Breast Cancer Patients After Systemic Therapy-Results From a Longitudinal Study.

Menning S, de Ruiter MB, Kieffer JM, Agelink van Rentergem J, Veltman DJ, Fruijtier A, Oldenburg HS, Boven E, van der Meij S, Lustig V, Bos ME, Boogerd W, Reneman L, Schagen SB.

J Pain Symptom Manage. 2016 Oct;52(4):560-569.e1. doi: 10.1016/j.jpainsymman.2016.04.012. Epub 2016 Sep 17.

PMID:
27650011
9.

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.

Geukes Foppen MH, Brandsma D, Blank CU, van Thienen JV, Haanen JB, Boogerd W.

Ann Oncol. 2016 Jun;27(6):1138-42. doi: 10.1093/annonc/mdw134. Epub 2016 Mar 8.

PMID:
26961150
10.

Neurobiological changes by cytotoxic agents in mice.

Seigers R, Loos M, Van Tellingen O, Boogerd W, Smit AB, Schagen SB.

Behav Brain Res. 2016 Feb 15;299:19-26. doi: 10.1016/j.bbr.2015.10.057. Epub 2015 Nov 18.

PMID:
26602283
11.

EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors.

Milojkovic Kerklaan B, Pluim D, Bol M, Hofland I, Westerga J, van Tinteren H, Beijnen JH, Boogerd W, Schellens JH, Brandsma D.

Neuro Oncol. 2016 Jun;18(6):855-62. doi: 10.1093/neuonc/nov273. Epub 2015 Nov 12.

12.

Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Milojkovic Kerklaan B, van Tellingen O, Huitema AD, Beijnen JH, Boogerd W, Schellens JH, Brandsma D.

J Neurol. 2016 Mar;263(3):428-40. doi: 10.1007/s00415-015-7919-9. Epub 2015 Oct 17. Review.

PMID:
26477024
13.

Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy.

Stouten-Kemperman MM, de Ruiter MB, Caan MW, Boogerd W, Kerst MJ, Reneman L, Schagen SB.

Hum Brain Mapp. 2015 Nov;36(11):4638-47. doi: 10.1002/hbm.22942. Epub 2015 Aug 25.

PMID:
26304182
14.

Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment--the role of fatigue.

Menning S, de Ruiter MB, Veltman DJ, Koppelmans V, Kirschbaum C, Boogerd W, Reneman L, Schagen SB.

Neuroimage Clin. 2015 Feb 20;7:547-54. doi: 10.1016/j.nicl.2015.02.005. eCollection 2015.

15.

Magnetic resonance imaging of the carotid artery in long-term head and neck cancer survivors treated with radiotherapy.

Wilbers J, Meijer FJ, Kappelle AC, Kaanders JH, Boogerd W, Dorresteijn LD, van Dijk EJ, Steens SC.

Acta Oncol. 2015;54(8):1175-80. doi: 10.3109/0284186X.2015.1023901. Epub 2015 Apr 1.

PMID:
25831144
16.

Late effects of adjuvant chemotherapy for breast cancer on fine motor function.

Hoogendam YY, Schagen SB, Ikram MA, Boogerd W, Seynaeve C, Seidler RD, Breteler MM, Van der Geest JN, Koppelmans V.

Psychooncology. 2015 Dec;24(12):1799-807. doi: 10.1002/pon.3796. Epub 2015 Mar 9.

PMID:
25756497
17.

Prevalence of cerebral small-vessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy.

Koppelmans V, Vernooij MW, Boogerd W, Seynaeve C, Ikram MA, Breteler MM, Schagen SB.

J Clin Oncol. 2015 Feb 20;33(6):588-93. doi: 10.1200/JCO.2014.56.8345. Epub 2015 Jan 5.

PMID:
25559803
18.

Very Late Treatment-Related Alterations in Brain Function of Breast Cancer Survivors.

Stouten-Kemperman MM, de Ruiter MB, Boogerd W, Veltman DJ, Reneman L, Schagen SB.

J Int Neuropsychol Soc. 2015 Jan;21(1):50-61. doi: 10.1017/S1355617714001015. Epub 2014 Dec 22.

PMID:
25529014
19.

Progression of carotid intima media thickness after radiotherapy: a long-term prospective cohort study.

Wilbers J, Dorresteijn LD, Haast R, Hoebers FJ, Kaanders JH, Boogerd W, van Werkhoven ED, Nowee ME, Hansen HH, de Korte CL, Kappelle AC, van Dijk EJ.

Radiother Oncol. 2014 Dec;113(3):359-63. doi: 10.1016/j.radonc.2014.10.012. Epub 2014 Nov 14.

PMID:
25466374
20.

Prospective cohort study of carotid intima-media thickness after irradiation.

Wilbers J, Hoebers FJ, Boogerd W, van Werkhoven ED, Nowee ME, Hart G, Bartelink H, van Dijk EJ, Kappelle AC, Dorresteijn LD.

J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2701-7. doi: 10.1016/j.jstrokecerebrovasdis.2014.06.009. Epub 2014 Oct 7.

PMID:
25304721
21.

Long term cerebral and vascular complications after irradiation of the neck in head and neck cancer patients: a prospective cohort study: study rationale and protocol.

Wilbers J, Kappelle AC, Kessels RP, Steens SC, Meijer FJ, Kaanders JH, Haast RA, Versteeg LE, Tuladhar AM, de Korte CL, Hansen HH, Hoebers FJ, Boogerd W, van Werkhoven ED, Nowee ME, Hart G, Bartelink H, Dorresteijn LD, van Dijk EJ.

BMC Neurol. 2014 Jun 19;14:132. doi: 10.1186/1471-2377-14-132.

22.

Cognitive impact of cytotoxic agents in mice.

Seigers R, Loos M, Van Tellingen O, Boogerd W, Smit AB, Schagen SB.

Psychopharmacology (Berl). 2015 Jan;232(1):17-37. doi: 10.1007/s00213-014-3636-9. Epub 2014 Jun 4.

PMID:
24894481
23.

Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials.

Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Junck L, van den Bent M, Wen PY, Jaeckle KA.

Neuro Oncol. 2014 Sep;16(9):1176-85. doi: 10.1093/neuonc/nou089. Epub 2014 May 27. Review.

24.

Neurotoxicity in breast cancer survivors ≥10 years post-treatment is dependent on treatment type.

Stouten-Kemperman MM, de Ruiter MB, Koppelmans V, Boogerd W, Reneman L, Schagen SB.

Brain Imaging Behav. 2015 Jun;9(2):275-84. doi: 10.1007/s11682-014-9305-0.

PMID:
24858488
25.

Chemotherapy-induced neuropathy: A comprehensive survey.

Miltenburg NC, Boogerd W.

Cancer Treat Rev. 2014 Aug;40(7):872-82. doi: 10.1016/j.ctrv.2014.04.004. Epub 2014 Apr 18. Review.

PMID:
24830939
26.

Outcome of patients with primary central nervous system lymphoma treated outside clinical trials.

Hart A, Baars JW, Kersten MJ, Brandsma D, van Tinteren H, de Jong D, Spiering M, Dewit L, Boogerd W.

Neth J Med. 2014 May;72(4):218-23.

27.

Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study.

Griffith KA, Dorsey SG, Renn CL, Zhu S, Johantgen ME, Cornblath DR, Argyriou AA, Cavaletti G, Merkies IS, Alberti P, Postma TJ, Rossi E, Frigeni B, Bruna J, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey DJ, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG; CI-PeriNomS Group.

J Peripher Nerv Syst. 2014 Jun;19(2):127-35. doi: 10.1111/jns5.12064.

28.

Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.

Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G; CI-PeriNomS Group.

Ann Oncol. 2014 Jan;25(1):257-64. doi: 10.1093/annonc/mdt409. Epub 2013 Nov 19.

29.

Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia.

Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Schagen SB.

Crit Rev Oncol Hematol. 2013 Oct;88(1):87-101. doi: 10.1016/j.critrevonc.2013.04.002. Epub 2013 Jun 13. Review.

PMID:
23768778
30.

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).

Binda D, Vanhoutte EK, Cavaletti G, Cornblath DR, Postma TJ, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Rossi E, Valsecchi MG, Faber CG, Merkies IS; CI-PeriNomS study group, Galimberti S, Lanzani F, Mattavelli L, Piatti ML, Bidoli P, Cazzaniga M, Cortinovis D, Lucchetta M, Campagnolo M, Bakkers M, Brouwer B, Boogerd W, Grant R, Reni L, Piras B, Pessino A, Padua L, Granata G, Leandri M, Ghignotti I, Plasmati R, Pastorelli F, Heimans JJ, Eurelings M, Meijer RJ, Grisold W, Lindeck Pozza E, Mazzeo A, Toscano A, Russo M, Tomasello C, Altavilla G, Penas Prado M, Dominguez Gonzalez C, Dorsey SG.

Eur J Cancer. 2013 Sep;49(13):2910-8. doi: 10.1016/j.ejca.2013.04.004. Epub 2013 May 10.

PMID:
23668917
31.

Neurological immune-related adverse events of ipilimumab.

Bot I, Blank CU, Boogerd W, Brandsma D.

Pract Neurol. 2013 Aug;13(4):278-80. doi: 10.1136/practneurol-2012-000447. Epub 2013 Mar 13.

PMID:
23487828
32.

Cluster-like headache and a cystic hypothalamic tumour as first presentation of sarcoidosis.

van der Vlist SH, Hummelink BJ, Westerga J, Boogerd W.

Cephalalgia. 2013 Apr;33(6):421-4. doi: 10.1177/0333102412475237. Epub 2013 Feb 12.

PMID:
23405019
33.

Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy.

Koppelmans V, de Groot M, de Ruiter MB, Boogerd W, Seynaeve C, Vernooij MW, Niessen WJ, Schagen SB, Breteler MM.

Hum Brain Mapp. 2014 Mar;35(3):889-99. doi: 10.1002/hbm.22221. Epub 2012 Dec 20.

PMID:
23281152
34.

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.

Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG; CI-PeriNomS Group.

Ann Oncol. 2013 Feb;24(2):454-62. doi: 10.1093/annonc/mds329. Epub 2012 Aug 21.

35.

Chemotherapy as primary treatment for brain metastases from breast cancer: analysis of 115 one-year survivors.

Boogerd W, Groenveld F, Linn S, Baars JW, Brandsma D, van Tinteren H.

J Cancer Res Clin Oncol. 2012 Aug;138(8):1395-403. doi: 10.1007/s00432-012-1218-y. Epub 2012 Apr 13.

PMID:
22526158
36.

Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy.

Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB.

J Clin Oncol. 2012 Apr 1;30(10):1080-6. doi: 10.1200/JCO.2011.37.0189. Epub 2012 Feb 27.

PMID:
22370315
37.

[Practice guideline 'Brain metastases' (revision)].

Gijtenbeek JM, Ho VK, Heesters MA, Lagerwaard FJ, de Graeff A, Boogerd W.

Ned Tijdschr Geneeskd. 2011;155(52):A4141. Review. Dutch.

PMID:
22217243
38.

Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy.

Koppelmans V, de Ruiter MB, van der Lijn F, Boogerd W, Seynaeve C, van der Lugt A, Vrooman H, Niessen WJ, Breteler MM, Schagen SB.

Breast Cancer Res Treat. 2012 Apr;132(3):1099-106. doi: 10.1007/s10549-011-1888-1. Epub 2011 Dec 29.

PMID:
22205140
39.

Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging.

de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, Lavini C, Linn SC, Boven E, van Dam FS, Schagen SB.

Hum Brain Mapp. 2012 Dec;33(12):2971-83. doi: 10.1002/hbm.21422. Epub 2011 Sep 23.

PMID:
22095746
40.

Incidental findings on brain Magnetic Resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy.

Koppelmans V, Schagen SB, Poels MM, Boogerd W, Seynaeve C, van der Lugt A, Breteler MM.

Eur J Cancer. 2011 Nov;47(17):2531-6. doi: 10.1016/j.ejca.2011.06.026.

PMID:
21745734
41.

Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study.

Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB.

Psychooncology. 2012 May;21(5):479-87. doi: 10.1002/pon.1928. Epub 2011 Feb 23.

PMID:
21351188
42.

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.

Taal W, Dubbink HJ, Zonnenberg CB, Zonnenberg BA, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Kros JM, Kouwenhoven MC, van Marion R, van Heuvel I, van der Holt B, Bromberg JE, Sillevis Smitt PA, Dinjens WN, van den Bent MJ; Dutch Society for Neuro-Oncology.

Neuro Oncol. 2011 Feb;13(2):235-41. doi: 10.1093/neuonc/noq177. Epub 2010 Dec 21.

43.

Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer.

de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FS, Nederveen AJ, Boven E, Schagen SB.

Hum Brain Mapp. 2011 Aug;32(8):1206-19. doi: 10.1002/hbm.21102. Epub 2010 Jul 28.

PMID:
20669165
44.

Severe encephalopathy and polyneuropathy induced by dichloroacetate.

Brandsma D, Dorlo TP, Haanen JH, Beijnen JH, Boogerd W.

J Neurol. 2010 Dec;257(12):2099-100. doi: 10.1007/s00415-010-5654-9. Epub 2010 Jul 15. No abstract available.

PMID:
20632025
45.

Re: Late effects from radiation therapy: the hits just keep on coming.

Aleman BM, de Bruin ML, Dorresteijn LD, Krol AD, van 't Veer MB, Boogerd W, van Leeuwen FE.

J Natl Cancer Inst. 2010 Apr 21;102(8):576-7; author reply 577-8. doi: 10.1093/jnci/djq069. Epub 2010 Mar 22. No abstract available.

PMID:
20308649
46.

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.

Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB.

J Clin Oncol. 2010 Mar 10;28(8):1294-300. doi: 10.1200/JCO.2008.21.3553. Epub 2010 Feb 8.

PMID:
20142601
47.

Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.

Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB.

Crit Rev Oncol Hematol. 2010 Nov;76(2):133-41. doi: 10.1016/j.critrevonc.2009.11.001. Epub 2009 Dec 24.

PMID:
20036141
48.

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ.

Neurology. 2009 Nov 24;73(21):1792-5. doi: 10.1212/WNL.0b013e3181c34ace.

PMID:
19933982
49.

Treatment modalities for leptomeningeal metastases.

Shapiro WR, Johanson CE, Boogerd W.

Semin Oncol. 2009 Aug;36(4 Suppl 2):S46-54. doi: 10.1053/j.seminoncol.2009.05.006. Review.

PMID:
19660683
50.

Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma.

De Bruin ML, Dorresteijn LD, van't Veer MB, Krol AD, van der Pal HJ, Kappelle AC, Boogerd W, Aleman BM, van Leeuwen FE.

J Natl Cancer Inst. 2009 Jul 1;101(13):928-37. doi: 10.1093/jnci/djp147. Epub 2009 Jun 17.

PMID:
19535773

Supplemental Content

Loading ...
Support Center